Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1584969
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Abl1
Name: ABL proto-oncogene 1, non-receptor tyrosine kinase
Acc ID: CHEBI:78543
Term: ponatinib
Definition: A benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I).
Chemical ID: MESH:C545373
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Abl1decreases activityISOABL1 (Homo sapiens)6480464CTDponatinib analog results in decreased activity of ABL1 protein; ponatinib analog results in decreased activity of ABL1 protein mutant form; ponatinib results in decreased activity of ABL1 protein; ponatinib results in decreased activity of ABL1 protein mutant formPMID:19878872 PMID:20513156 PMID:21561767 PMID:22781593
Abl1decreases phosphorylationISOABL1 (Homo sapiens)6480464CTDponatinib results in decreased phosphorylation of ABL1 protein; ponatinib results in decreased phosphorylation of ABL1 protein mutant formPMID:19878872 PMID:25304212
Abl1multiple interactionsISOABL1 (Homo sapiens)6480464CTDponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of ABL1 protein mutant form]; ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; ponatinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein]PMID:19878872
Go Back to source page   Continue to Ontology report